Medicus Pharma (NASDAQ:MDCX) Issues Quarterly Earnings Results

Medicus Pharma (NASDAQ:MDCX – Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.13), Zacks reports.

Medicus Pharma Trading Down 10.7%

Shares of NASDAQ MDCX traded down $0.04 during midday trading on Friday, hitting $0.30. The company’s stock had a trading volume of 1,110,629 shares, compared to its average volume of 4,453,618. The stock has a fifty day moving average price of $0.43 and a 200 day moving average price of $1.23. Medicus Pharma has a one year low of $0.25 and a one year high of $8.94. The firm has a market capitalization of $12.59 million, a price-to-earnings ratio of -0.11 and a beta of -0.47.

Get Medicus Pharma alerts:

Institutional Trading of Medicus Pharma

Hedge funds and other institutional investors have recently modified their holdings of the business. Jane Street Group LLC bought a new stake in shares of Medicus Pharma in the second quarter valued at approximately $41,000. HRT Financial LP bought a new stake in Medicus Pharma during the 4th quarter worth approximately $42,000. Osaic Holdings Inc. increased its holdings in Medicus Pharma by 180.0% during the 2nd quarter. Osaic Holdings Inc. now owns 14,000 shares of the company’s stock worth $42,000 after acquiring an additional 9,000 shares during the period. Commonwealth Equity Services LLC increased its holdings in Medicus Pharma by 161.8% during the 4th quarter. Commonwealth Equity Services LLC now owns 28,493 shares of the company’s stock worth $44,000 after acquiring an additional 17,611 shares during the period. Finally, Wilmington Savings Fund Society FSB bought a new stake in Medicus Pharma during the 3rd quarter worth approximately $59,000.

Wall Street Analysts Forecast Growth

Several analysts have commented on MDCX shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Medicus Pharma in a research report on Friday, April 10th. D. Boral Capital reissued a “buy” rating and issued a $9.00 price target on shares of Medicus Pharma in a research report on Monday, April 20th. Finally, Roth Mkm assumed coverage on shares of Medicus Pharma in a research report on Tuesday, April 21st. They issued a “buy” rating on the stock. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Medicus Pharma presently has a consensus rating of “Hold” and an average target price of $9.00.

Read Our Latest Research Report on MDCX

Medicus Pharma Company Profile

(Get Free Report)

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.

Read More

• Five stocks we like better than Medicus Pharma
• Viking Sails to All-Time Highs—Fundamentals Signal More to Come
• Datavalut Gains Traction: 5 Reasons to Sell Now
• TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
• The Power Grid Is Dying—Is It Time to Buy Its Replacement?

Receive News & Ratings for Medicus Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicus Pharma and related companies with MarketBeat.com's FREE daily email newsletter.